Solide Tumoren - Geschlechtsorgane und Brust - Keimzelltumoren -
Weiterführende Informationen

Leitlinien

Krege S et al: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I + II. Eur Urol 2008; 53: 478–96 and 497–513

Cathomas R et al: Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011; 34:59–64

EAU Leitlinien

Studien

Aktuelle deutsche Studien: www.hodenkrebs.de (deutsche Hodentumor-Studiengruppe), internationale Studien: www.eortc.be (Europa) oder www.clinicaltrials.gov (USA). Derzeit aktiv sind Studien zum Stadium I (cSI) bei Nicht-Seminomen, für Pat. mit platinrefraktärer Erkrankung sowie 2 Registerstudien.

Literatur

Aktuelle Literatur über www.hodenkrebs.de zu erhalten (mit unregelmäßigen Updates)

1. Albers P et al, German Testicular Cancer Study Group: Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008; 26: 2966–72
2. Albers P et al, EAU guidelines on testicular cancer: 2011 update. Eur Urol 2011; 60: 304–19
3. Bokemeyer C et al, German Testicular Cancer Study Group: Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Ann Oncol 2008; 19: 448–53
4. De Wit R et al, A randomized phase III study comparing paclitaxel-PEB (T-PEB) to standard PEB in patients with an intermediate prognosis germ cell cancer: An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). Proc ASCO, J Clin Oncol 2011; 29(s): Abstract 4509
5. International Prognostic Factors Study Group: Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010; 28: 4906-11
6. Krege S et al: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I + II. Eur Urol 2008; 53: 478–96 und 497–513
7. Lorch A et al, German Testicular Cancer Study Group: Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 2778–84
8. Lorch A et al: Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178–84
9. Mead GM et al: Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. JNCI 2011; 103: 241–9
10. Oechsle K et al: Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 2011; 60: 850–5
11. Tandstadt T et al: Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122–8